ANI Pharmaceuticals, Inc. ANIP

ANI Pharmaceuticals, Inc. es una empresa biofarmacéutica diversificada que sirve a pacientes necesitados mediante el desarrollo, fabricación y comercialización de productos farmacéuticos de marca y genéricos con receta, incluidos para enfermedades con una alta necesidad médica no satisfecha. La Compañía se enfoca en lograr un crecimiento sostenible al expandir su negocio de Enfermedades Raras a través de su activo principal, Purified Cortrophin Gel, así como su negocio de genéricos con capacidades mejoradas de investigación y desarrollo. Sus tres instalaciones de fabricación farmacéutica, dos ubicadas en Baudette, Minnesota, y una ubicada en East Windsor, Nueva Jersey, son capaces de producir productos en forma de dosis sólidas orales, así como semisólidos, líquidos y tópicos, sustancias controladas y productos potentes. La Compañía tiene un portafolio comercial de aproximadamente 118 productos con una variedad de indicaciones y un sólido portafolio de productos en desarrollo.

• GlobeNewswire Inc. 24 jul

  ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

  ANI Pharmaceuticals announced it will release its second quarter 2026 financial results on August 7, 2026, with executives hosting a webcast and conference call. The company also announced positive six-month topline data from its Phase 4 SYNCHRONICITY trial evaluating fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis, meeting both co-primary endpoints.

  

• GlobeNewswire Inc. 13 jul

  ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

  ANI Pharmaceuticals reported positive Phase 4 trial results for ILUVIEN (fluocinolone acetonide intravitreal implant) in treating chronic non-infectious uveitis affecting the posterior segment. The trial met both co-primary endpoints with statistically significant improvements in visual acuity (+3.6 letters) and central subfield thickness reduction (-157.5 microns) at 6 months. Safety profile was consistent with prior trials, with ocular hypertension (6%) and cataract (5%) as the most common adverse events.

  

• The Motley Fool 12 jul

  ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run

  ANI Pharmaceuticals CFO Stephen Carey sold 3,313 shares worth $285,000 on July 2, 2026, through a pre-established Rule 10b5-1 trading plan adopted in March. The sale represented only 2% of his direct holdings, leaving him with approximately $15.3 million in company stock. The transaction involved exercising options at $49.51 and selling at $86.00 per share. Despite the stock's 32% one-year return, the article characterizes this as routine portfolio management, noting the company's strong fundamentals including 20.5% Q1 revenue growth and raised full-year guidance.